Tempest Minerals Ltd

Tempus AI successfully priced a $650 million convertible senior notes offering, increasing from the initially announced $400 million, to fund its AI-enabled precision medicine platform development.

Ambry Genetics' CARE Program demonstrated 99.5% accuracy in interpreting NCCN Clinical Practice Guidelines for hereditary cancer risk assessment in a peer-reviewed study published in the Journal of the National Comprehensive Cancer Network.

Biovica International announces aggressive financial targets, projecting net sales growth from SEK 8.5 million in FY 2024/25 to SEK 150 million by FY 2026/27.

Tempus AI and Verastem Oncology have announced a collaboration to develop a companion diagnostic test for the recently FDA-approved combination therapy of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

Tempus AI has formed the TIME Precision Network, connecting investigators across over 40 phase I-capable research centers to expedite clinical trial activation and patient enrollment.

Tempus AI has launched xM for treatment response monitoring (TRM), a liquid biopsy assay designed to detect molecular response to immune-checkpoint inhibitor therapy in advanced solid tumors by tracking circulating tumor DNA dynamics.

Tempus AI has launched Loop, a novel oncology-focused platform that integrates real-world patient data with human-derived biological models and CRISPR screens to accelerate target discovery and validation.

Tempus AI has announced a multi-year strategic collaboration with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology, secured by a $200 million agreement for data licensing and model development.

Tempus AI has announced strategic collaborations with AstraZeneca and Pathos AI to develop a multimodal foundation model in oncology, with agreements totaling $200 million in data licensing and model development fees.

• Tempus AI has acquired Deep 6 AI, a leading precision research platform that matches patients to clinical trials by analyzing real-time electronic medical record data across healthcare ecosystems. • The strategic acquisition expands Tempus AI's provider network and enhances its ability to deploy critical applications including Next for closing care gaps and TIME for connecting patients to potentially lifesaving clinical trials. • Eric Lefkofsky, Founder and CEO of Tempus, highlighted that Deep 6's integration infrastructure complements Tempus's connectivity efforts to support physicians in delivering optimized patient care.